Liaoning Chengda Biotechnology Stock Current Valuation
| 688739 Stock | 26.96 0.36 1.35% |
Valuation analysis of Liaoning Chengda Bio helps investors to measure Liaoning Chengda's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Liaoning Chengda's Free Cash Flow is projected to decrease significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 6.1 B, whereas Cash is forecasted to decline to about 3.4 B. Fundamental drivers impacting Liaoning Chengda's valuation include:
Price Book 1.16 | Enterprise Value 5.7 B | Enterprise Value Ebitda 13.3211 | Price Sales 6.5203 | Trailing PE 33.2099 |
Overvalued
Today
Please note that Liaoning Chengda's price fluctuation is not too volatile at this time. Calculation of the real value of Liaoning Chengda Bio is based on 3 months time horizon. Increasing Liaoning Chengda's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Liaoning Chengda is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Liaoning Stock. However, Liaoning Chengda's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 26.96 | Real 22.49 | Hype 26.96 | Naive 26.52 |
The real value of Liaoning Stock, also known as its intrinsic value, is the underlying worth of Liaoning Chengda Bio Company, which is reflected in its stock price. It is based on Liaoning Chengda's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Liaoning Chengda's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Liaoning Chengda Biotechnology helps investors to forecast how Liaoning stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Liaoning Chengda more accurately as focusing exclusively on Liaoning Chengda's fundamentals will not take into account other important factors: Liaoning Chengda Biotechnology Company Current Valuation Analysis
Liaoning Chengda's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Liaoning Chengda Current Valuation | 5.74 B |
Most of Liaoning Chengda's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Liaoning Chengda Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Liaoning Chengda Biotechnology has a Current Valuation of 5.74 B. This is 60.05% lower than that of the Biotechnology sector and 23.54% higher than that of the Health Care industry. The current valuation for all China stocks is 65.48% higher than that of the company.
Liaoning Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Liaoning Chengda's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Liaoning Chengda could also be used in its relative valuation, which is a method of valuing Liaoning Chengda by comparing valuation metrics of similar companies.Liaoning Chengda is currently under evaluation in current valuation category among its peers.
Liaoning Fundamentals
| Return On Equity | 0.0346 | ||||
| Return On Asset | 0.0239 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.37 % | ||||
| Current Valuation | 5.74 B | ||||
| Shares Outstanding | 416.45 M | ||||
| Shares Owned By Insiders | 61.24 % | ||||
| Shares Owned By Institutions | 2.14 % | ||||
| Price To Book | 1.16 X | ||||
| Price To Sales | 6.52 X | ||||
| Revenue | 1.75 B | ||||
| Gross Profit | 1.57 B | ||||
| EBITDA | 506.9 M | ||||
| Net Income | 465.92 M | ||||
| Total Debt | 4.86 M | ||||
| Book Value Per Share | 23.20 X | ||||
| Cash Flow From Operations | 677.01 M | ||||
| Earnings Per Share | 0.81 X | ||||
| Target Price | 40.0 | ||||
| Number Of Employees | 1.73 K | ||||
| Beta | 0.71 | ||||
| Market Capitalization | 11.2 B | ||||
| Total Asset | 10.08 B | ||||
| Retained Earnings | 4.04 B | ||||
| Working Capital | 6.89 B | ||||
| Annual Yield | 0.03 % | ||||
| Net Asset | 10.08 B | ||||
| Last Dividend Paid | 0.8 |
About Liaoning Chengda Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Liaoning Chengda Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Liaoning Chengda using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Liaoning Chengda Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Liaoning Stock
Liaoning Chengda financial ratios help investors to determine whether Liaoning Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Liaoning with respect to the benefits of owning Liaoning Chengda security.